Asian Journal of Medical Principles and Clinical Practice

The Benefits and Risks of PPI Use in H. Pylori Associated Peptic Ulcer Disease

Hossamaldin Fawzy Ramadan Alshorfa *

Burjeel Royal Hospital, Al Ain, United Arab Emirates.

*Author to whom correspondence should be addressed.

---

Abstract

Helicobacter pylori (H. pylori) infection is one of the most common causative factors of peptic ulcers, which may affect the stomach and the duodenum. Proton pump inhibitors (PPIs) have become a key ingredient of H. pylori-associated ulcers due to their highly acid-suppressive properties. Numerous clinical trials have proved that PPIs have a beneficial effect on the ulcer healing process in those with H. pylori infection. PPIs are acid pump inhibitors that irreversibly inhibit the H+/K+ ATPase proton pump in gastric parietal cells. Through this mechanism, PPIs reduce the secretion of gastric acid, allowing for a conducive environment that is favorable for ulcer healing. Meta-analyses have repeatedly shown that triple therapy with PPI (proton pump inhibitor) achieves higher ulcer healing rates compared to antibiotics therapy alone, which again stresses the synergistic effect of acid suppression and H. pylori eradication. PPI, in ulcer healing, remains indispensable, however, their effects on the regimen for eradication of H. pylori needs to be considered. PPIs are commonly used as one of the three main components of the standard triple therapy regimen in addition to antibiotics. Nevertheless, the risk of affecting the efficiency of H. pylori eradication using PPIs has been raised. Research may suggest that PPI use can decrease pH in the stomach, thereby compromising the action of antibiotics against H. pylori. Despite their efficacy, PPIs are associated with various risks and adverse effects. Long-term PPI use has been linked to an increased risk of enteric infections, including Clostridioides difficile-associated diarrhea, potentially attributable to altered gut microbiota and reduced gastric acidity. This literature review will examine PPI in the context of H. pylori infection, its efficacy in the treatment of ulcers, and related risks.

Keywords: Helicobacter pylori, H. pylori infection, proton-pump inhibitors, PPIs, stomach acidity, gastrointestinal tract issues

---

---

---

References

Parikh NS, Ahlawat R. Helicobacter Pylori. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available:http://www.ncbi.nlm.nih.gov/books/NBK534233/

Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014 Dec;34(4):771–85.

Ceylan A, Kırımi E, Tuncer O, Türkdoğan K, Arıyuca S, Ceylan N. Prevalence of Helicobacter pylori in Children and Their Family Members in a District in Turkey. J Health Popul Nutr. 2007 Dec;25(4):422–7.

Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of helicobacter pylori infection: clinical features, treatment, and nutritional aspects. Diseases. 2021 Sep 23;9(4):66.

Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nat Rev Dis Primer. 2023 Apr 20;9(1):19.

Ahmed A, Clarke JO. Proton Pump Inhibitors (PPI). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available:http://www.ncbi.nlm.nih.gov/books/NBK557385/

Proton pump inhibitors. In: LiverTox: Clinical and research information on drug-induced liver injury. Bethesda (MD): National institute of diabetes and digestive and kidney Diseases; 2012. Available:http://www.ncbi.nlm.nih.gov/books/NBK547892/

Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528–34.

Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023; 79(9):1159–72.

Nagaraja V, Eslick GD. Evidence-based assessment of proton-pump inhibitors in Helicobacter pylori eradication: A systematic review. World J Gastroenterol WJG. 2014 Oct 28;20(40):14527–36.

Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol. 2019 Sep 14;25(34):5097–104.

Nasser SC, Slim M, Nassif JG, Nasser SM. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol WJG. 2015 Apr 21;21(15): 4599–606.

Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14:179.

Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol. 2022 Jun 28;28(24):2667–79.

Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308–28; quiz 329.

Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013 May;108(5):679–92; quiz 693.

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005 Jan 19;97(2):142–6.

Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003 Jan; 98(1):51–8.

Calatayud S, García-Zaragozá E, Hernández C, Quintana E, Felipo V, Esplugues JV, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2002 Dec; 283(6):G1360-1367.

Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991 Mar;35(3):490–6.

Chey WD, Wong BCY, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):1808–25.

Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PloS One. 2008 Jul 30;3(7):e2836.

Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001 Mar;15(3): 379–88.

Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998 Jan;12(1): 99–104.

Zilberstein B, Quintanilha AG, Santos MAA, Pajecki D, Moura EG, Alves PRA, et al. Digestive tract microbiota in healthy volunteers. Clin Sao Paulo Braz. 2007 Feb;62(1):47–54.